Insider Selling: Annexon (NASDAQ:ANNX) Insider Sells $26,979.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,290 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the sale, the insider owned 73,152 shares of the company’s stock, valued at approximately $373,075.20. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Annexon Stock Performance

NASDAQ:ANNX opened at $4.90 on Monday. The company has a market capitalization of $586.19 million, a P/E ratio of -3.48 and a beta of 1.17. The stock’s 50 day moving average price is $5.58 and its 200 day moving average price is $3.96. Annexon, Inc. has a 52 week low of $1.28 and a 52 week high of $7.18.

Institutional Investors Weigh In On Annexon

Hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Annexon in the second quarter valued at about $29,000. 49 Wealth Management LLC bought a new stake in Annexon during the 2nd quarter valued at approximately $29,000. CIBC Bancorp USA Inc. acquired a new stake in Annexon in the 3rd quarter valued at approximately $31,000. Engineers Gate Manager LP bought a new position in Annexon in the 2nd quarter worth approximately $32,000. Finally, SG Americas Securities LLC bought a new position in Annexon in the 3rd quarter worth approximately $34,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ANNX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Chardan Capital assumed coverage on Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target for the company. Finally, Wells Fargo & Company raised their price objective on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Key Annexon News

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.